Keywords
hemojuvelin
iron metabolism
How to Cite
Abstract
The hepcidin is a peptide hormone produced by the liver with anti-bacterial activity, is involved in regulation iron metabolism, making it possible to use it as another parameter to assess some entities related to disorders associated with iron metabolism. Hepcidin regulates intestinal absorption of iron level and the role of ferroportin in the cell, preventing either iron overload or iron consumption reserve, this is turn regulating for inflammatory stimuli, iron store, erythropoietic activity and signaling patway SMAD,STAT and JAK; in this signaling patway involved a membrane protein called hemojuvelin. The hemojuvelin acts as a bone morphogenetic protein co-receptor, they induce hepcidin gene transcription through the SMAD1/5/8-SMAD4. Because of the associations of hemojuveline with hepcidin expression and the relationship of the latter with inflammatory processes and regulations of iron metabolism have been proposed some techniques for the determination of both proteins as Elisa, Dotblot, Immunoassays and SELDI-TOF MS.
Mackenzie S. Anemia por defecto en la síntesis del hem. En: Hematología clínica. 2a ed. México: Manual Moderno; 2000. p. 145-75.
Kemna E et al. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93(1): 90-7.
Viatte L, Vaulont S. Hepcidin: the iron watcher. J Biochi. 2009;91:1223-8.
Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta.
;1763:700-10.
Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38:531-9.
Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933-9.
Singh B, Sarika A, Poonam A, Gupta SK. Hepcidin: A novel peptide hormone regulating iron metabolism. Clin Chim Acta. 2011;412(11-12):823-30.
Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated. Blood. 2005;106:2884-9.
Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. 2002;277:37597-603.
De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI et al. The molecular mechanism of hepcidin-mediated ferroportin downregulation. Mol Biol Cell. 2007;18(7):2569-78.
Wallace DF, Jones MD, Pedersen P, Rivas L, Sly LI, Subramaniam VN. Purification and partial characterization of recombinant human hepcidin. Biochimie. 2006;88:31-7.
Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the live. J Biol Chem. 2001;276:7806-10.
Kemna EHJM, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53:620-8.
Malyszko J. Hemojuvelin: the hepcidin story continues. Kidney Blood Press Res. 2009;32:71-6.
Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cell Mol Dis. 2008;40:122-31.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-3.
De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA. 2005;102:8955-60.
Ganz T. Hepcidin and iron regulation, 10 years later. Blood.
;117(17):4425-33.
Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N et al. Identification of an intestinal heme transporter. Cell. 2005;122:789-801.
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I et al. Hepcidin: a new iron regulatory peptide J Clin Invest. 2002;110:1037-44.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK et al. IL-6 mediates hypoferremia in inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-6.
Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106:1864-6.
Verga Falzacappa MV, Spasic MV, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT-3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353-8.
Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-44.
Maxson JE, Enns CA, Zhang A-S. Processing of hemojuvelin requires retrograde trafficking to the Golgi in HepG2 cells. Blood. 2009;113(8):1786-93.
Mok H, Mlodnicka AE, Hentze MW, Muckenthaler M, Schumacher A. The molecular circuitry regulating the switch between iron deficiency and overload in mice. J Biol Chem. 2006;281:7946-51.
Lou DQ, Lesbordes JC, Nicolas G, Viatte L, Bennoun M, Van Rooijen N, Kahn A, Renia L, Vaulont S. Iron-and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. Hepatology. 2005;41:1056-64.
Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204-9.
Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone morphogenetic protein (BMP-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med. 2008;86:531-40.
Papanikolaou G et al. Mutations in HFE2 cause iron overload in chromosome 1qlinked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood. 2004;103:4669-71.
Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte cultura through hemojuvelin and BMP2/4. Blood. 2007;110:2182-9.
Reis Lemos A, Silva IL, Carvalho MC, Frota Borges MT, De Carvalho Rondó PH. Hepcidin as a biochemical parameter for the assessment of iron deficiency anemia. Rev Assoc Med Bras. 2010;56(5):596-9.
Bayele HK, McArdle H, Srai SKS. Cis and trans regulation of hepcidin expression y upstream stimulatory factor. J Am Soc Haematol. 2006;108:4237-45.
Hugman A. Hepcidin: an important new regulator of iron homeostasis. Clin Lab Haematol. 2006;28:75-83.
Papanikolaou G, Tzilianaos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103-5.
Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Messa PG, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol. 2007;27:101-7.
Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function. Blood. 2005;106:746-8.
Weinstein David, Roy Cindy N, Fleming Mark D, Loda Massimo F, Wolfsdorf Joseph I, Andrews Nancy C. Anemia: implications for the anemia of chronic disease Inappropriate expression of hepcidin is associated with iron refractory. Blood. 2002;100:3776-81.
Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip system. Blood. 2006;108:1381-7.
Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W. Pro-hepcidin: expression and cell
specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut. 2004;53:735-43.
Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292-7.
Weiss G, Goodnough LT. Anemia of chronic disease. J Med. 2005;352:1011-23.
Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55(6):667-74.
Pak M, López MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FWK, Chapman R, Maxwell PH, and Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematol. 2010;95:505-8.
Brookes MJ, Sharma NK, Tselepis C, Iqbal TH. Serum pro-hepcidin: measuring active hepcidin or non-functional precursor? Gut. 2005;54:169-70.
Roe MA, Spinks C, Heath AL, Harvey LJ, Foxall R, Wimperis J et al. Serum prohepcidin concentration: no association with iron absorption in healthy men, and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant woman. Br J Nutr. 2007;97:544-9.
Koliaraki V, Marinou M, Vassilakopoulos
TP, Vavourakis E, Tsochatzis E, Pangalis
GA. A novel immunological assay
for hepcidin quantification in human serum.
PLoS ONE. 2009;4(2):1-7.
Kemna E, Tjalsma H, Laarakkers C, Nemeth
E, Willems H, Swinkels D. Novel
urine hepcidin assay by mass spectrometry.
Blood. 2005;106:3268-70.
Brasse-Lagnel C, Céline Lesueur M,
Grandchamp B et al. Immunoassay for
human serum hemojuvelin. Haematologica.
;95(12):2031-7.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.